[Pharmacotherapy in HFrEF].
Copyright policy )[Pharmacotherapy in HFrEF].
Since publication of the European Society guidelines for the diagnosis and treatment of acute and chronic heart failure in 2016, numerous studies provided new evidence how to further optimize heart failure therapy.Besides recent device-based therapeutic options, promising new drug developments give a glimmer of hope that the prognosis of this progressive heart disease could be somehow more controlled in the near future. At the same time, the variety of therapeutic options as well as the number of concomitant comorbidities makes the complex therapy of chronic heart failure more difficult than ever. This review aims to provide an update and practical support on the recent pharmacotherapeutic options in chronic heart failure.
Heart Failure, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Agents, Stroke Volume, Comorbidity, Prognosis, Chronic Disease, Humans, Mineralocorticoid Receptor Antagonists
Heart Failure, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Agents, Stroke Volume, Comorbidity, Prognosis, Chronic Disease, Humans, Mineralocorticoid Receptor Antagonists
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!